Repositorio Dspace

Management of patients with heart failure treated in cardiology consultations: IC-BERG Study

Mostrar el registro sencillo del ítem

dc.contributor.author Barríos, V
dc.contributor.author Escobar, C
dc.contributor.author Ortiz-Cortes, C
dc.contributor.author Cosin-Sales, J
dc.contributor.author Pascual-Figal, Domingo-Andrés
dc.contributor.author García-Moll-Marimon, X
dc.date.accessioned 2025-05-09T10:08:35Z
dc.date.available 2025-05-09T10:08:35Z
dc.date.issued 2020-08
dc.identifier.citation Barrios V, Escobar C, Ortiz Cortés C, Cosín Sales J, Pascual Figal DA, García-Moll Marimón X. Management of patients with heart failure treated in cardiology consultations: IC-BERG Study. Rev Clin Esp (Barc). 2020;220(6):339-49.
dc.identifier.issn 0014-2565
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/19000
dc.description.abstract OBJECTIVE: To determine the perception and management of heart failure with reduced ejection fraction (HFrEF) by clinical cardiologists and to establish a consensus with recommendations. METHODS: We employed the modified Delphi method among a panel of 150 experts who answered a questionnaire that included three blocks: definition and perception of patients with «stable» HFrEF (15 statements), management of patients with «stable» HFrEF (51 statements) and recommendations for optimising the management and follow-up (9 statements). The level of agreement was assessed with a Likert 9-point scale. RESULTS: A consensus of agreement was reached on 49 statements, a consensus of disagreement was reached on 16, and 10 statements remained undetermined. There was consensus regarding the definition of «stable» HF (82%), that HFrEF had a silent nature that could increase the mortality risk for mildly symptomatic patients (96%) and that the drug treatment should be optimised, regardless of whether a patient with HFrEF remains stable in the same functional class (98.7%). In contrast, there was a consensus of disagreement regarding the notion that treatment with an angiotensin receptor-neprilysin inhibitor is justified only when the functional class worsens (90.7%). CONCLUSIONS: Our current understanding of «stable» HF is insufficient, and the treatment needs to be optimised, even for apparently stable patients, to decrease the risk of disease progression.
dc.language.iso spa
dc.publisher EDICIONES DOYMA S A
dc.rights Atribución-NoComercial-SinDerivadas 4.0 España
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.title Management of patients with heart failure treated in cardiology consultations: IC-BERG Study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 32111439
dc.relation.publisherversion https://dx.doi.org/10.1016/j.rce.2019.10.011
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1016/j.rce.2019.10.011
dc.journal.title Revista Clinica Espanola
dc.identifier.essn 1578-1860


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 4.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 4.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta